Golidocitinib API is a pharmaceutical-grade selective Janus Kinase 1 (JAK1) inhibitor developed for the treatment of hematological malignancies, particularly relapsed or refractory peripheral T-cell lymphoma (PTCL). By selectively inhibiting the JAK1 signaling pathway, Golidocitinib helps suppress abnormal cytokine signaling involved in tumor cell proliferation, survival, and inflammation.
Its targeted mechanism of action offers the potential for improved therapeutic outcomes while reducing off-target effects associated with non-selective kinase inhibitors. Golidocitinib is being utilized in advanced oncology research and targeted treatment strategies for hematologic cancers.
Swapnroop Drugs and Pharmaceuticals manufactures premium-quality Golidocitinib API under stringent WHO-GMP manufacturing standards. Every batch undergoes comprehensive quality testing for purity, stability, assay, impurities, and regulatory compliance. Complete documentation including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), and technical specifications is available.
Golidocitinib API is supplied in pharmaceutical-grade HDPE containers or fiber drums suitable for research and commercial manufacturing.
Available Packaging Options:
Each shipment includes:
Golidocitinib API is primarily used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and is being studied for additional hematologic malignancies.
It selectively inhibits Janus Kinase 1 (JAK1), blocking cytokine-mediated signaling pathways that contribute to cancer cell growth and survival.
It belongs to the Selective JAK1 Inhibitor class of targeted anticancer therapies.
Yes. We provide Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), technical specifications, and complete regulatory documentation.
Yes. We supply Golidocitinib API in commercial quantities with worldwide export support and customized packaging.
Get Bulk Quote via WhatsApp